Skip to main content
Ibrutinib offers better efficacy and tolerability over idelalisib+rituximab in relapsed/refractory CLL
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Ibrutinib offers better efficacy and tolerability over idelalisib+rituximab in relapsed/refractory CLL
User login
Username
Password
Reset your password
Concept
Lead
score
Chronic Lymphocytic Leukemia
1
1
Leukemia
0
1
Prognosis
0
0.85
Refractory
0
0.5
Antineoplastic Drug
0
0.25
Monoclonal Antibody
0
0.85
Biologic Therapy
0
0.95
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
0.36
Edit Tags